8-Isoprostaglandin E2 activates Ca2+-dependent K + current via cyclic AMP signaling pathway in murine renal artery

European Journal of Pharmacology

Volumn 520, Issue 1-3, 2005, Pages 22-28

  Zhang, Yongde ^a   Pertens, Evi ^a   Janssen, Luke J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cyclic AMP; Isoprostane; K+ channel; Protein kinase A; Rho Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINOPYRIDINE; 8 ISOPROSTAGLANDIN E2; 9 (TETRAHYDRO 2 FURYL)ADENINE; CALCIUM ION; CHARYBDOTOXIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ISOPROSTANE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; POTASSIUM ION; RUTHENIUM RED; RYANODINE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RENAL ARTERY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE;

ADENINE; ADENYLATE CYCLASE; ANIMALS; BIOLOGICAL FACTORS; CALCIUM; CYCLIC AMP; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOPROSTANES; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PROTEIN KINASE INHIBITORS; RENAL ARTERY; SIGNAL TRANSDUCTION;

EID: 25444472142     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.08.009     Document Type: Article

References (15)

1. 2 Am. J. Physiol., Lung Cell. Mol. Physiol. 287 2004 L1035 L1041
2. A. Catalli, D. Zhang, and L.J. Janssen Receptor and signaling pathway underlying relaxations to isoprostanes in canine and porcine airway smooth muscle Am. J. Physiol., Lung Cell. Mol. Physiol. 283 2002 L1151 L1159
3. J.L. Cracowski, and O. Ormezzano Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases Eur. Heart J. 25 2004 1675 1678
4. J.L. Crocowski, T. Durand, and G. Bessard Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications Trends Pharmacol. Sci. 23 2002 360 365
5. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 351 2000 95 105
6. L.J. Janssen Isoprostanes, an overview and putative roles in pulmonary pathophysiology Am. J. Physiol., Lung Cell. Mol. Physiol. 280 2001 L1067 L1082
7. L.J. Janssen Are endothelium-derived hyperpolarizing and contracting factors isoprostanes? Trends Pharmacol. Sci. 23 2002 59 62
8. L.J. Janssen The pulmonary biology of isoprostanes Chem. Phys. Lipids 128 2004 101 116
9. L.J. Janssen, and T. Tazzeo Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature J. Pharmacol. Exp. Ther. 301 2002 1060 1066
10. L.J. Janssen, M. Premji, S. Netherton, A. Catalli, G. Cox, S. Keshavjee, and D.J. Crankshaw Excitatory and inhibitory actions of isoprostanes in human and canine airway smooth muscle J. Pharmacol. Exp. Ther. 295 2000 506 511
11. L.J. Janssen, M. Premji, S. Netherton, J. Coruzzi, H. Lu-Chao, and P.G. Cox Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles Br. J. Pharmacol. 132 2001 127 134
12. J.D. Morrow Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers New Engl. J. Med. 332 1995 1198 1203
13. M. Uehata, T. Ishizaki, H. Satoh, T. Ono, T. Kawahara, T. Morishita, H. Tamakawa, K. Yamagami, J. Inui, M. Maekawa, and S. Narumiya Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 1997 990 994
14. 2+-sensitization Am. J. Respir. Cell Mol. Biol. 20 1999 1190 1200
15. 2 in porcine coronary artery J. Pharmacol. Exp. Ther. 305 2003 1054 1060